Johnson & Johnson has proposed a settlement agreement valued at up to $5.5 billion to resolve tens of thousands of pending lawsuits related to its talc-based baby powder products. The pharmaceutical and consumer healthcare giant’s latest offer represents a significant increase from previous settlement attempts and aims to end litigation that has spanned more than a decade, with plaintiffs claiming the company’s talcum powder products caused ovarian cancer and mesothelioma.
The proposed settlement amount will be distributed over a multi-year payment schedule and must receive approval from at least 75 percent of current claimants through a bankruptcy process. This enhanced offer comes after two previous attempts to resolve the litigation through subsidiary bankruptcies were rejected by federal courts. The Food and Drug Administration has been monitoring talc-containing cosmetic products for potential asbestos contamination, though the agency has not established definitive cancer risks from cosmetic talc use.
Johnson & Johnson discontinued sales of its talc-based baby powder in North America in 2020 and globally in 2023, transitioning entirely to cornstarch-based formulations. The company has consistently maintained that its talc products are safe and asbestos-free, stating that decades of scientific research support the safety of cosmetic talc. Despite these assertions, the mounting legal costs and reputational impact prompted the settlement strategy.
The litigation encompasses approximately 61,000 pending claims filed in various jurisdictions across the United States. Plaintiffs, predominantly women, alleged that prolonged use of Johnson’s Baby Powder and Shower-to-Shower products for feminine hygiene purposes caused them to develop ovarian cancer. Additional lawsuits involved individuals diagnosed with mesothelioma, a rare cancer associated with asbestos exposure, claiming that asbestos contamination in the talc products caused their illness.
Financial analysts view the settlement proposal as a strategic move to eliminate significant legal liabilities from Johnson & Johnson’s balance sheet and restore focus to its pharmaceutical and medical device divisions. The company separated its consumer health division, which included the baby powder product line, into an independent entity called Kenvue in 2023. This corporate restructuring was partly motivated by the desire to insulate the more profitable pharmaceutical operations from ongoing talc litigation risks.
Previous settlement attempts through the bankruptcy of subsidiary LTL Management were dismissed by appellate courts, which ruled that Johnson & Johnson itself was not in financial distress and therefore could not use the bankruptcy system to resolve mass tort claims. The current proposal takes a different legal approach by seeking to achieve the required claimant support threshold before initiating bankruptcy proceedings, potentially strengthening the settlement’s legal foundation.
Legal experts indicate that the success of this settlement offer depends heavily on plaintiff attorney recommendations and individual claimant acceptance rates. Some plaintiffs’ lawyers have expressed skepticism about the adequacy of the compensation amount given the number of claims involved, while others view it as a reasonable resolution that provides certain compensation rather than protracted litigation with uncertain outcomes.
The talc litigation has cost Johnson & Johnson billions in legal fees, jury verdicts, and settlements over the past decade, with some individual jury awards exceeding $2 billion before being reduced on appeal. The company has won some trials while losing others, creating an unpredictable litigation landscape that complicated resolution efforts. Industry observers note that this settlement, if approved, would rank among the largest mass tort resolutions in pharmaceutical industry history, comparable to opioid-related settlements by other major drug manufacturers.